The estimated Net Worth of Harlan S Robins is at least $9.47 millió dollars as of 4 March 2022. Harlan Robins owns over 4,517 units of Adaptive Biotechnologies stock worth over $1,369,504 and over the last 5 years he sold ADPT stock worth over $5,693,449. In addition, he makes $2,409,520 as Co-Founder és Chief Scientific Officer at Adaptive Biotechnologies.
Harlan has made over 35 trades of the Adaptive Biotechnologies stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 4,517 units of ADPT stock worth $54,249 on 4 March 2022.
The largest trade he's ever made was exercising 100,000 units of Adaptive Biotechnologies stock on 19 January 2021 worth over $632,000. On average, Harlan trades about 24,516 units every 20 days since 2020. As of 4 March 2022 he still owns at least 311,960 units of Adaptive Biotechnologies stock.
You can see the complete history of Harlan Robins stock trades at the bottom of the page.
Dr. Harlan S. Robins Ph.D. serves as Co-Founder, Chief Scientific Officer of the Company. Dr. Robins has served in various roles in the Computational Biology Program at Fred Hutch, including as an Assistant Faculty Member from 2006 to 2011, as an Associate from 2011 to April 2016 and as a Full Member and the Head of the program from April 2016 to June 2019. Dr. Robins holds a BS in Physics from Harvard University and a master’s degree and PhD in Physics from the University of California, Berkeley with a visiting appointment to the California Institute of Technology. Dr. Robins received postdoctoral appointments in the particle theory group at the Weizmann Institute of Science in Israel and at the Institute for Advance Study at Princeton University. At Princeton, Dr. Robins developed bioinformatics algorithms for micro RNA targets and bacterial genome analysis.
As the Co-Founder és Chief Scientific Officer of Adaptive Biotechnologies, the total compensation of Harlan Robins at Adaptive Biotechnologies is $2,409,520. There are 2 executives at Adaptive Biotechnologies getting paid more, with Lance Baldo having the highest compensation of $3,707,390.
Harlan Robins is 46, he's been the Co-Founder és Chief Scientific Officer of Adaptive Biotechnologies since 2009. There are 18 older and 5 younger executives at Adaptive Biotechnologies. The oldest executive at Adaptive Biotechnologies Corporation is Peter Neupert, 64, who is the Lead Independent Director.
Harlan's mailing address filed with the SEC is C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVENUE EAST, SEATTLE, WA, 98109.
Over the last 5 years, insiders at Adaptive Biotechnologies have traded over $685,617,014 worth of Adaptive Biotechnologies stock. The most active insiders traders include Global Investors Lp Viking ..., Global Performance Llc Viki... és Kevin T Conroy. On average, Adaptive Biotechnologies executives and independent directors trade stock every 6 days with the average trade being worth of $368,167. The most recent stock trade was executed by Stacy L Taylor on 22 August 2024, trading 26,922 units of ADPT stock currently worth $121,149.
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It also has a research collaboration with Curebase, Inc. to enhance patient participation in clinical studies. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Adaptive Biotechnologies executives and other stock owners filed with the SEC include: